PerkinElmer: Human Health And Environmental Sales A Drag
Zacks Investment Research | Nov 20, 2016 08:20PM ET
On Nov 18, we issued an updated research report on Waltham, MA-based PerkinElmer, Inc. (NYSE:PKI) – a leading global provider of scientific instruments, consumables, and services to pharmaceutical, biomedical and environmental testing markets. The company currently carries a Zacks Rank #4 (Sell).
Over the last 30 days, the Zacks Consensus Estimate for full-year 2016 earnings fell by 4 cents to $2.76 per share. The stock recorded an earnings surprise of 3.03% in the last reported quarter and has a long-term expected earnings growth rate of almost 11.3%.
PerkinElmer ended the third quarter on a mixed note wherein adjusted earnings surpassed management’s guided range and the Zacks Consensus Estimate. However, revenues lagged the guided range and also deteriorated on a year-over-year basis.
Human Health and Environmental revenues declined massively on a year-over-year basis in the just-reported quarter, due to softer capital equipment end-markets. Additionally, lower-than-estimated sales in the U.S. and Europe caused a drag on Environmental sales.
The decline in sales at the Medical Imaging segment raises concern. PerkinElmer faced significant headwinds in the radiochemical and capital-intensive businesses as well.
Additionally, management’s decision to eliminate certain slower growth segments from the priority list has marred the short-term prospects for PerkinElmer.
We believe a sluggish European macro-economic environment and restrained spending and challenges in Japan are also likely to hurt the top line in the near term.
Nevertheless, with an enhanced focus on product innovation and expansion into emerging markets like China, PerkinElmer holds considerable promise for the coming quarters.
Key Picks
Better-ranked stocks in the broader medical space include Cogentix Medical, Inc. (NASDAQ:CGNT) , CryoLife Inc. (NYSE:CRY) and IDEXX Laboratories, Inc. (NASDAQ:IDXX) . Notably, IDEXX Laboratories and Cogentix sport a Zacks Rank #1 (Strong Buy) while CryoLife has a Zacks Rank #2 (Buy). You can see Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.